New Treatment of Common Wart

April 18, 2026 updated by: Bassma Alaaeldin Mohamed, Sohag University

Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts

this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • - Age more than or equal to 18 years
  • Clinically and dermoscopically confirmed Common warts of both sex
  • patient not receiving previous treatment at least one month before recruitment in our study
  • Single or multiple lesions suitable for injection.

Exclusion Criteria:

  • Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .

Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: group 1 PRF injection
Biological: PRF group
intralesional PRF injection in common warts
Active Comparator: group 2 vitamin D injection
Drug: Vitamin D
intralesional vitamin D injection in common wart

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )
Time Frame: 1 session every 2 weeks for 3 months
treatment of common wart by intralesional injection of PRF
1 session every 2 weeks for 3 months
changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )
Time Frame: 6 months after the last session
6 months after the last session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 6, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

December 30, 2026

Study Registration Dates

First Submitted

April 1, 2026

First Submitted That Met QC Criteria

April 18, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-26-3-16MS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Common Warts (Verruca Vulgaris)

Clinical Trials on PRF group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe